- Home
- HYLN vs NGNE Comparison
HYLN vs NGNE Comparison
Compare HYLN & NGNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HYLN
- NGNE
- Stock Information
- Founded
- HYLN 2018
- NGNE 2003
- Country
- HYLN United States
- NGNE United States
- Employees
- HYLN N/A
- NGNE N/A
- Industry
- HYLN Construction/Ag Equipment/Trucks
- NGNE Biotechnology: Pharmaceutical Preparations
- Sector
- HYLN Consumer Discretionary
- NGNE Health Care
- Exchange
- HYLN Nasdaq
- NGNE Nasdaq
- Market Cap
- HYLN 279.7M
- NGNE 325.3M
- IPO Year
- HYLN N/A
- NGNE N/A
- Fundamental
- Price
- HYLN $1.64
- NGNE $20.51
- Analyst Decision
- HYLN Hold
- NGNE Strong Buy
- Analyst Count
- HYLN 1
- NGNE 7
- Target Price
- HYLN $2.00
- NGNE $41.86
- AVG Volume (30 Days)
- HYLN 954.1K
- NGNE 123.0K
- Earning Date
- HYLN 08-12-2025
- NGNE 08-11-2025
- Dividend Yield
- HYLN N/A
- NGNE N/A
- EPS Growth
- HYLN N/A
- NGNE N/A
- EPS
- HYLN N/A
- NGNE N/A
- Revenue
- HYLN $3,513,000.00
- NGNE N/A
- Revenue This Year
- HYLN $575.94
- NGNE N/A
- Revenue Next Year
- HYLN $255.00
- NGNE N/A
- P/E Ratio
- HYLN N/A
- NGNE N/A
- Revenue Growth
- HYLN 3559.38
- NGNE N/A
- 52 Week Low
- HYLN $1.11
- NGNE $6.88
- 52 Week High
- HYLN $4.10
- NGNE $74.49
- Technical
- Relative Strength Index (RSI)
- HYLN 55.12
- NGNE 47.72
- Support Level
- HYLN $1.47
- NGNE $18.94
- Resistance Level
- HYLN $1.69
- NGNE $21.59
- Average True Range (ATR)
- HYLN 0.10
- NGNE 1.40
- MACD
- HYLN 0.01
- NGNE -0.26
- Stochastic Oscillator
- HYLN 77.42
- NGNE 32.30
About HYLN Hyliion Holdings Corp.
Hyliion Holdings Corp provides solutions that enable clean, flexible, and affordable electricity production. The Company focuses on delivering distributed power generators that can operate on various fuel sources to future-proof against an ever-changing energy economy. It is initially targeting the commercial and waste management industries with a locally deployable generator that can offer prime power as well as energy arbitrage opportunities. In addition to stationary power solutions, it focuses on mobile applications, including vehicles and marine technologies.
About NGNE Neurogene Inc.
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.